Transmedics Group, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
TransMedics Group, Inc. reported significant revenue growth and net income for fiscal year 2025, driven by its OCS technology and National OCS Program, despite identifying a material weakness in internal controls.
NASDAQ
TransMedics Group, Inc. reports significant revenue growth and achieves profitability in 2024, driven by adoption of its Organ Care System (OCS) and National OCS Program (NOP).
NASDAQ
TransMedics Group, Inc. secures additional financial backing and expands its operational capabilities through a series of agreements and acquisitions, including the assumption of debt and the purchase of an aviation company.